Show simple item record

dc.creatorParvathaneni, Vineela
dc.creatorGupta, Vivek
dc.date.accessioned2020-08-31T14:26:25Z
dc.date.available2020-08-31T14:26:25Z
dc.date.created2020
dc.identifier.issn0024-3205spa
dc.identifier.otherhttps://doi.org/10.1016/j.lfs.2020.118275spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/12452
dc.description.abstractThe recent outbreak of Coronavirus disease (COVID-19), first in Eastern Asia and then essentially across the world has been declared a pandemic by the WHO. COVID-19 is caused by a novel virus SARS-CoV2 (2019-nCoV), against which there is currently no vaccine available; and current antiviral therapies have failed, causing a very high mortality rate. Drug repurposing i.e. utilizing an approved drug for different indication, offers a time- and cost-efficient alternative for making new therapies available to patients. Although there are several reports presenting novel approaches to treat COVID-19, still an attentive review of previous scientific literature is essential to overcome their failure to exhibit efficacy. There is an urgent need to provide a comprehensive outlook toward utilizing drug repurposing as a tool for discovery of new therapies against COVID-19. In this article, we aim to provide a to-the-point review of current literature regarding efficacy of repurposed drugs against COVID-19 and other respiratory infections caused by coronaviruses. We have briefly discussed COVID-19 epidemiology, and then have discussed drug repurposing approaches and examples, specific to respiratory viruses. Limitations of utilization of repurposed drug molecules such as dosage regimen and associated challenges such as localized delivery in respiratory tract have also been discussed in detail.spa
dc.format.extent32 páginasspa
dc.format.mimetypeimage/jepgspa
dc.language.isoengspa
dc.publisherLife Sciencesspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCovid-19spa
dc.subjectDrug repurposingspa
dc.subjectFDA approved drugsspa
dc.subjectSARS-CoV2spa
dc.subjectLocalized deliveryspa
dc.titleUtilizing drug repurposing against COVID-19 – Efficacy, limitations, and challengesspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.identifier.doihttps://doi.org/10.1016/j.lfs.2020.118275spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record